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Abstract
Background: Migraine is highly prevalent in women (18%). Peak morbidity affects their most productive years, coin-
ciding with peak fertility. Hormonal contraception is often tailored for migraine prevention. Estrogen-containing contra-
ceptives may be contraindicated in women experiencing migraine with aura due to the risk of vascular events. While
improvements in migraine with a progestin-only pill (POP), which inhibits ovulation are documented, the strength and
quality of evidence has not been formally evaluated.
Objectives: To determine the effectiveness of progestin-only contraceptives for migraine treatment by systematic
review and meta-analysis.
Data sources and selection: MEDLINE, EMBASE and Cochrane Libraries were searched (1980 to September 2016)
for studies on progestin-only treatments for migraine. Studies in English on >4 non-menopausal women aged 18–50 with
migraine diagnosed by formal criteria were included.
Data extraction and analysis: Data were quality-assessed using the GRADE system. A random effects model was
used for pooled analyses.
Results: Pooled analyses of four studies demonstrated that desogestrel 75mcg/day, POP significantly but modestly
reduced the number of migraine attacks and migraine days. Reduced intensity and duration, reduced analgesic and triptan
use were observed, along with improved headache-related quality of life. GRADE analysis indicated evidence was low to
very low for each outcome measure. Adverse effects resulted in treatment cessation for <10% of participants. Two
studies compared desogestrel POP to a combined oral contraceptive, demonstrating similar migraine outcomes for both
treatments.
Conclusions: The desogestrel POP shows promise in improving migraine in women. Current evidence is observational
and based on small samples of women using only one oral progestin-only formulation. Further randomized trials on
additional progestin-only contraceptives are required to confirm their role in migraine management.
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Introduction
Description of the condition
Migraine is common, aﬀecting approximately 18% of
women and 6% of men (1), translating to its ranking as
the third most prevalent disorder and seventh highest
speciﬁc cause of disability in the Global Burden of
Disease Survey of 2010 (2). Migraines in women are a
signiﬁcant health issue, not just because of their high
prevalence, but also because of their distinct relation-
ship with hormonal changes (3). Migraines typically
worsen or begin with the onset of menarche and they
commonly occur with menstruation (known as men-
strual migraine) for up to 60% of women (4). This
peak in incidence coincides with a woman’s most pro-
ductive years, aﬀecting her personal relationships and
having a notable economic burden due to a loss of
productivity and work absenteeism, long term need
for medications and recurrent visits to health care pro-
fessionals (5,6).
Available treatments for migraine
Conventional management of migraine involves symp-
tomatic treatment for acute attacks and consideration
of daily preventative medication for those with fre-
quent migraine. For acute migraine, agents such as
non-steroidal anti-inﬂammatory drugs (NSAIDs), trip-
tans and anti-emetics in varying combinations may be
eﬀective (7,8). For patients experiencing frequent
migraine and/or migraine causing impairment, the use
of daily preventative treatments such as propanolol,
amytriptyline, pizotifen or topiramate, are recom-
mended (1).
Ovarian hormones are likely to modulate the noci-
ceptive and anti-nociceptive pathways involved in
migraine pathogenesis (9,10). Furthermore, menstru-
ation appears to be one of the most prominent factors
implicated in the occurrence or persistence of headache
and migraine (11). As mentioned above, 60% of women
with migraine have menstrual exacerbation. Both ovu-
lation and menstrual bleeding patterns can be poten-
tially manipulated by the use of hormonal therapies,
thereby potentially altering migraine. Hence, whilst
not ﬁrst-line management, a clinician may also consider
tailoring a female migraineur’s choice of contraception
or gynaecological treatment, particularly if hormonal
sensitivity of migraine is evident.
A recent systematic review documented low-
level evidence for the use of various combined oral
contraceptive pills (COCs), oestrogen gel and gonado-
tropin-releasing hormone agonists (12) in the treatment
of menstrual migraine. However, there are signiﬁcant
limitations to the use of COCs documented in
WHO and international guidelines (13,14), particularly
the two to four-fold increased risk of stroke in
women who experience migrainous aura (15) and
prevalent comorbidities such as advancing age over
35 and smoking status (13,14). One third of women
with migraine experience aura, therefore the cohort of
patients unable to use the COC is sizeable (16).
Furthermore, COCs have been reported to have a vari-
able impact on migraine, worsening migraine in some
women (4).
Progestin-only treatments for migraine
Given the contraindications to combined hormonal
contraceptive (CHC) use in a signiﬁcant proportion
of female migraine suﬀerers, including all women
with migraine with aura (MA), progestin-only contra-
ceptives are increasingly considered as an alternative
for patients with migraine, particularly those experien-
cing migraine with aura. World Health Organisation
and UK Faculty of Sexual and Reproductive Health
Medical Eligibility Criteria state that progestin-only
contraceptives are generally considered safe for
use in women with risk factors for stroke including
MA (13,14). Recent clinical reviews report improve-
ments in migraine symptoms with a relatively high-
dose progestin-only pill (POP), the desogestrel
75microgram/day pill (17,18). Despite this, the
strength and quality of evidence on POPs for migraine
treatment has not been formally evaluated. The mech-
anism of progestin in reducing migraine frequency and
intensity is largely unknown, but may relate to inhib-
ition of ovulation and modulation of nociceptive path-
ways (17).
Study objective
To determine the eﬀectiveness of POPs for migraine
treatment in pre-menopausal women aged 18–50 by
systematic review and meta-analysis.
Method
The systematic review and meta-analysis were prepared
using the Meta-analysis Of Observational Studies in
Epidemiology checklist (19), Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (20)
and Review Manager 5.3 software (21).
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Search strategy
A comprehensive literature search of Cochrane library,
MEDLINE AND EMBASE was performed by two
investigators (SW, CR). Search terms were across
three categories and included 1) migraine or headache,
2) progesterone, progestin, progestogen, or desogestrel
and 3) treatment or contraceptive. The MEDLINE
searching procedure is included in Appendix A
(Supplementary material). Additional relevant studies
were identiﬁed in Scopus and Google Scholar as well
as reference lists of treatment and review articles.
Inclusion and exclusion criteria
Inclusion and exclusion criteria as well as outcome
measures were selected prior to the literature search,
based on the International Headache Society’s
Guidelines for controlled trials of drugs in migraine
(22), where appropriate. Excluded studies including
reason for exclusion are listed in Appendix B
(Supplementary material).
Types of studies. All prospective and retrospective studies
published in English (1980 – September 2016), in which
progestin-only contraceptives were used for the man-
agement of migraine in women, were included.
Studies in a language other than English were included
if a reliable English translation could be obtained.
Review articles and case series with less than four par-
ticipants were excluded.
Type of participants. Studies on women (aged 18–50) with
MA, migraine without aura (MO) and menstrual
migraine were included. Study participants were diag-
nosed with migraine by any edition of the International
Headache Society criteria (23) or another reasonable
criterion, by a physician. Studies on pregnant women
and participants on hormone-replacement therapy for
menopausal symptoms were excluded.
Type of interventions. Studies with at least one arm inves-
tigating progestin-only contraceptives for migraine
management were included. Comparator arms, such
as groups receiving no treatment, or treatment with
CHCs or other medical treatments for migraine, were
acceptable. For all study groups, use of acute analgesia
or rescue medications was permitted, but these needed
to be recorded.
Types of outcome measures for use in meta-analysis. To
determine treatment eﬀectiveness, studies needed to
include one of the outcome measures of interest. The
primary outcome measure was the number of migraine
attacks following 180 days of treatment with a proges-
tin-only treatment. Secondary outcome measures
included 1) number of days with migraine; 2) duration
of migraine; 3) average headache intensity; 4) number
of symptomatic pain medications and triptans used;
5) Headache-related quality of life scores; and 6) rates
and types of adverse events.
Data extraction and quality assessment
Studies were reviewed by two authors (SW,CR) to deter-
mine eligibility for the study based on the inclusion and
exclusion criteria. The Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
approach (24) was used, as recommended by the
Cochrane Collaboration (25) to evaluate the quality of
evidence for each outcomemeasure. TheGRADE rating
was also performed by two authors (SW, CR) and dis-
crepancies were resolved by consensus.
Meta-analysis
Point estimates at baseline and at 90 days and 180 days
post-initiation of treatment were extracted for all out-
come measures. To perform the meta-analysis for each
POP pre- and post-treatment outcome, a random
eﬀects generic-inverse variance model was used to com-
bine point-estimates in RevMan, specialist software
produced by the Cochrane Collaboration (21). Tau-
squared was calculated using the DerSimonian and
Laird method (26). Correlations between results at
baseline and 90-day and 180-day point estimates were
not reported in any included studies, so these were
assumed to be zero to produce the most conservative
results. p-values are reported with no adjustment for
multiplicity of analyses.
Rates of adverse eﬀects associated with
desogestrel POP use were computed from study data
and 95% conﬁdence intervals were calculated using
Wilson’s method in OpenEpi (27). For adverse eﬀects
of desogestrel compared to the COC, risk diﬀerences
were calculated using a Mantel-Haenzsel random
eﬀects model and days with bleeding analysis was per-
formed with a continuous random eﬀects model, both
in RevMan (21).
Results
Included studies
Six studies met the inclusion and exclusion criteria for
the study and were considered eligible for the system-
atic review. However, upon further correspondence
with the authors of the Swiss studies, it was conﬁrmed
that one study (28) was an extension of two 2013 stu-
dies (29,30) so these earlier studies were excluded to
avoid biasing pooled analyses with duplicated
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participant data. One eligible study in German was
also excluded as no translation could be obtained
from the authors. Details of the searching process and
application of inclusion and exclusion criteria
are shown in Figure 1. Characteristics of the four
included studies (28,31–33) are shown in Table 1. All
studies reported pre- and post-treatment data for a des-
ogestrel 75microgram/day POP. Two of the included
studies (32,33) additionally compared the POP to a
COC (containing desogestrel 150 micrograms and ethi-
nylestradiol 20 micrograms) after 90 and 180 days’
treatment. Nappi et al. (31) examined two diﬀerent
groups with MA, one with previous COC use and one
without. Results for both groups were eligible for inclu-
sion, so have been reported separately in the meta-
analysis.
GRADE evaluation
The summary of GRADE ﬁndings for each outcome
measure can be seen in Table 2, and details of the
GRADE process can be found in Appendix C
(Supplementary material). All studies were observa-
tional with no randomization or placebo-controlled
groups, resulting in low GRADE ratings. Eﬀect sizes
for all outcome measures were modest, based on clin-
ical signiﬁcance of each outcome measure, so no out-
come measures could be upgraded in GRADE analysis.
Primary outcome measure: POP pre-treatment vs.
post-treatment
Forest plots for each outcome measure are presented in
Appendix D, Figures 1–13 (Supplementary material)
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Figure 1. PRISMA flowchart detailing data identification, screening, eligibility and inclusion.
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and mean diﬀerences with p-values for each outcome
measure at 180 days are presented in Table 2. Pooled
analysis showed that the number of attacks of migraine
per month was signiﬁcantly decreased at 180 days post-
treatment, compared with baseline. However, the size
of this mean random eﬀect was modest, with 0.64 fewer
migraine attacks per month at 90 days and 0.96 fewer
migraine attacks per month at 180 days. The women
had a mean migraine frequency of 4.43 migraines per
month in the pre-treatment period.
Secondary outcome measures: POP pre-treatment
vs. post-treatment
Pooled analyses found small but signiﬁcant reductions
in the number of days with migraine per month, aver-
age headache intensity and number of pain medications
used per month at both post-treatment time points.
Signiﬁcant reductions in duration of migraine and use
of triptans following 180 days of POP use were also
observed, compared with the pre-treatment baseline.
However, random eﬀects for these outcomes were not
signiﬁcant 90-days post-treatment.
Quality of life scores at 90 days and 180 days. Merki-Feld
et al. (28) examined the eﬀects of the POP on partici-
pants’ Migraine Disability Assessment (MIDAS) scores
at 90 days and 180 days post-treatment. A mean change
(improvement) in total MIDAS score of 18.00
(p< 0.001) was observed, as well as a signiﬁcant reduc-
tion in all individual MIDAS items (p< 0.001 –
p¼ 0.046). Morotti et al. (32,33) also reported signiﬁ-
cant improvements in quality of life, related to POP
use, measured using two subscales of the Short Form-
36 version 2 (SF36v2) questionnaire (34) (p< 0.001 for
both subscales in both studies). However, insuﬃcient
data were reported to facilitate meta-analysis of these
results.
Adverse events at 180 days. Adverse eﬀects resulted in
treatment cessation for 9.9% of participants across
the four studies (see Table 3). The most frequent of
these were prolonged bleeding and worsening of
migraine, and the majority of adverse events (18/20)
resulted in treatment cessation before 90 days.
Morotti et al. (32) also reported an increase in migraine
days per month in 4/31 (12.9%) participants and
Table 1. Characteristics of studies identified for inclusion systematic review and meta-analysis.
Study Design
No of
experimental
participants
(n¼ )
Age mean
(Standard
deviation)
Diagnostic
criteria
Prophylactic
medications
permitted Follow-up Treatment
Merki-Feld,
Switzerland,
2015 (28)
R, CS 42 35.1 (8.9) MO and MA
as per IHS
Yes, but
no change
90 days,
180 days
Desogestrel
75mcg/day
pre vs. post
Morotti, Italy,
2014a (33)
R, cohort 31 30.3 (2.9) MO as per
ICHD-II
No 90 days,
180 days
Desogestrel
75mcg/day
pre vs. post
Desogestrel
150mcg and
ethinylestradiol
20mcg pre
vs. post
Morotti, Italy,
2014b (32)
P, cohort 62 30.4 (3) MO as per
ICHD-II
No 90 days,
180 days
Desogestrel
75mcg/day
pre vs. post
Desogestrel
150mcg and
ethinylestradiol
20mcg pre
vs. post
Nappi, Italy,
2011 (31)
P, cohort Group A, 15;
Group B, 15
Group A¼ 30.6
(5.4),
Group B¼ 31.5
(6.5)
MA as per
ICHD-II
No 90 days,
180 days
Desogestrel
75mcg/day
pre vs post
P: prospective; R: restrospective; CS: case series (with pre and post-test data); cohort: cohort study; MO: migraine without aura, MA: migraine with
aura; pre: pre-treatment; post: post-treatment
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Merki-Feld et al. (28) reported an increase in migraine
and headache days in 7/42 (16.7%) participants, but
these participants did not withdraw from treatment.
Effects of interventions: Desogestrel 75mcg/day
POP vs. a desogestrel-containing COC
Two included studies also compared the desogestrel
POP to a COC containing desogestrel 150mcg and ethi-
nylestradiol 20mcg. Pooled analysis of most outcomes
could not be performed as the studies used diﬀering
outcome measures and diﬀering COC regimes. In
both studies, there were no signiﬁcant diﬀerences in
baseline demographic characteristics between the POP
and COC groups.
Morotti et al. (32) examined the eﬀects of the deso-
gestrel POP, compared to continuous use (i.e. with no
pill-free interval) of the desogestrel-containing COC in
women with MO. The POP and COC group had no
diﬀerences in migraine days per month, average head-
ache intensity, pain medication use and triptan use,
after 90 days of treatment. After 180 days of treatment,
the POP group reported signiﬁcant improvements in
headache-related quality of life (measured by SF-
36v2, p< 0.001 for both subscales), an eﬀect that was
not seen in the COC group. However, when directly
compared, no diﬀerences in SF-36v2 scores between
the two groups were found. The participants using
the POP also reported slightly less pain medication
use at 180 days (mean diﬀerence¼ 1.0, p¼ 0.044) than
participants on the COC pill.
Morotti et al. (33) examined the eﬀects of the deso-
gestrel POP (n¼ 55), which is used continuously (with-
out a hormone-free interval), compared to the same
desogestrel-containing COC, with the prescribed hor-
mone-free interval (n¼ 62) in women with MO and
rectovaginal endometriosis. The POP group had signiﬁ-
cantly fewer migraine attacks than the COC group after
both 90 days (mean diﬀerence¼1.1 attacks/month,
p< 0.001) and 180 days of treatment (mean
diﬀerence¼1.04 attacks/month, p< 0.001). Migraine
attacks were also signiﬁcantly shorter (mean diﬀer-
ence¼2.94 hours, p< 0.001 at 90 days, with a similar
eﬀect at 180 days) and less intense (mean diﬀer-
ence¼0.29 on a four-point rating scale, p< 0.001 at
90 days, with a similar eﬀect at 180 days) in the POP
group compared to the COC group.
Adverse effects and days with bleeding: POP compared to COC
at 180 days. No signiﬁcant diﬀerences in risk of adverse
eﬀects causing treatment cessation between the
POP and the COC were observed (see Table 4). Data
from two studies showed signiﬁcantly fewer days with
bleeding following 180 days of treatment with the
COC, compared to the POP (see Appendix C,
Figure 13, Supplementary material).
Discussion
Summary of main results
This systematic review examines the current evidence
for the use of a POP for migraine management in
women. A comprehensive literature search found only
four observational studies that met the inclusion cri-
teria, all of which examined the eﬀects of a single
POP containing desogestrel 75 micrograms per day
over a 180-day treatment period. None of the included
studies were randomised. Meta-analysis demonstrated
that the POP reduces the number of migraine attacks
and number of days with migraine per month at
90 days and 180 days post-treatment, compared with
the pre-treatment baseline. However, the eﬀect size was
small and likely reﬂects variability in treatment
response between women. In fact, two included studies
(28,33) found that days with migraine or headache
increased post-POP treatment in 12.9–16.7% of
women. However, Merki-Feld et al. observed a 25%
post-treatment reduction in the number of headache
Table 4. Risk differences for adverse effects leading to treat-
ment cessation, associated with POP compared to COC in
Morotti, 2014a and Morotti, 2014b.
Adverse effect POP CHP
Risk difference
[95% C.I.] p value
Any adverse effect 12/10 23/113 0.06 [0.21, 0.09] 0.43
Prolonged bleeding 8/105 6/113 0.03 [0.04, 0.09] 0.41
Worsened migraine 2/105 11/113 0.07 [0.16, 0.02] 0.11
Weight gain 1/105 2/113 0.00 [0.04, 0.03] 0.79
Peripheral oedema 1/105 1/113 0.00 [0.03, 0.03] 0.87
Other e.g. acne,
mood changes,
decreased libido
0/105 3/113 0.02 [0.06, 0.02] 0.29
Table 3. Adverse effects leading to treatment cessation, related
to use of desogestrel 75mcg/day.
No/total no of
participants
at 180 days Rate 95% C.I.
Any adverse effects 20/203 9.9% 6.47% –14.73%
Prolonged bleeding 12/203 5.9% 3.41% –10.05%
Worsened migraine 5/203 2.5% 1.06% –5.64%
Weight gain 1/203 0.5% 0.09% –2.74%
Peripheral oedema 1/203 0.5% 0.09% –2.74%
Acne 1/203 0.5% 0.09% –2.74%
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and migraine days in 55% of participants, and a
30% reduction in pain was observed in 60% of partici-
pants (28).
The desogestrel POP was also associated with a sig-
niﬁcant reduction in the duration of migraine and a
reduction in the use of triptans 180 days after com-
mencement of treatment, but not at 90 days. The
POP also reduced the number of pain medications
required throughout the post-treatment period.
Merki-Feld et al. (28) reported a substantial improve-
ment in MIDAS scores associated with the POP.
Overall, the quality of evidence for the POP in treating
migraine is considered low to very low for all outcome
measures (see Table 2 and Appendix C, Supplementary
material), indicating that future research is likely to
alter the eﬀects for each outcome measure.
Two studies directly compared women using the des-
ogestrel POP to women using a COC containing deso-
gestrel-ethinylestradiol. Given that our review searched
widely on progestin-only contraceptives for migraine
treatment, it is likely that these are the only two current
studies in English comparing the COC with the POP for
migraine treatment. One study (33) showed minimal
diﬀerences in migraine symptoms between women on
the POP compared to a COC used continuously, with-
out a hormone-free break. However, the second study
(32), found that the POP was associated with signiﬁcant
reductions in frequency, duration and intensity of
migraine attacks, compared with the COC used with
a regular withdrawal period, for women with MO and
comorbid rectovaginal endometriosis. Although POPs
are typically associated with unpredictable bleeding
patterns (35), pooled analysis of adverse eﬀects in our
study showed similar risks of adverse eﬀects, including
prolonged bleeding, in women with MO on both the
POP and the COC.
Overall completeness and applicability of evidence
No studies had placebo-controlled or randomised
groups, as this may be ethically diﬃcult with drugs
that aﬀect fertility, but two studies compared the POP
to the COC as a likely alternative approach. In general,
however, the lack of control groups is a signiﬁcant limi-
tation of the current evidence on progestin-only treat-
ments for migraine, as improvements noted may be due
to the natural history of migraine, regression to the
mean or amelioration due to the passage of time (22).
The GRADE analysis indicated a low to very low qual-
ity of evidence for each outcome measure. In particular,
the duration of migraine outcome was downgraded, as
one group in Nappi et al. (31), who had never taken
COCs, experienced a slight increase in migraine dur-
ation following treatment with the POP. The average
headache intensity outcome was also downgraded for
indirectness, as the averaging method used means it is
more likely a measure of migraine morbidity (both
intensity and frequency) rather than intensity alone
(see Appendix C, Supplementary material).
Meta-analysis of all reported quality of life data was
impeded by unavailability of post-treatment means and
standard deviations in two studies (32,33), although
improvements in headache-related quality of life were
reportedly signiﬁcant in these studies. Similarly,
although all studies followed the International
Headache Society guidelines in principle (22), there
was inconsistency between studies in the computation
of averaged outcomes (e.g. average headache intensity
and pain medications used). In our review, two studies
(one with a COC control group) used ‘‘number of
migraine attacks per month’’ and two studies (the
other with COC control group) used ‘‘number of
migraine days per month’’, reducing the total partici-
pant data for each outcome. Although ‘‘number of
migraine attacks’’ is considered the superior primary
eﬃcacy measure in International Headache Society
guidelines (22), it is possible that ‘‘days with migraine’’
data is more reliably collected by participants, poten-
tially explaining the inconsistency between studies.
Despite the extensive literature search, data for this
meta-analysis was limited to a single POP, the desoges-
trel 75mcg/day pill, whose positive eﬀects on migraine
may be related to the inhibition of ovulation (8). It is
likely that similar eﬀects may be seen with the etono-
gestrel implant, which also inhibits ovulation (36).
However, other progestin-only treatments such as the
LNG-IUS, which exerts its hormonal action at a local
level within the uterus, rather than through inhibition
of ovulation, or the lower-dose POPs, which act pri-
marily through their eﬀect on cervical mucus, may
have not have the same eﬀect on migraine. It is possible
that amenorrhoea may also impact on migraine symp-
toms (37), which may provide an additional mechanism
for contraceptives such as the etonogestrel implant and
LNG-IUS. The practical application of these ﬁndings is
also geographically-speciﬁc, as the desogestrel 75mcg/
day pill is not approved for clinical use in some coun-
tries including Australia.
In discussing the generalisability of ﬁndings, it is also
important to consider the types of participants included
in each study as well as their diagnosis and clinical
presentation. All included studies utilised the widely-
accepted diagnostic criteria of the International
Headache Society (ICHD-II) and between the included
studies, data for women with both MO and MA is
available (see Table 1). Only Merki-Feld et al. (28)
included women on preventative medication (with no
regime changes permitted, see Table 1) and a small
number of women (n¼ 6) with chronic daily headache,
so the results of this meta-analysis are more likely to
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apply to women with less frequent or severe migraines.
Morotti et al. (32) compared the eﬀects of the POP and
the COC on diﬀerent migraine patterns including pure
menstrual migraine (PMM), menstrually-related
migraine (MRM) and non-menstrual migraine
(NMM). They found that women with NMM on the
POP had fewer migraine attacks than women with
NMM on the COC (p< 0.001). Additionally, women
with PMM and MRM on the POP had less intense
migraine attacks than those with PMM and MRM on
the COC (p< 0.001).
Implications for future research
Migraine in women is not a trivial issue. In addition to
the morbidity for the individual, the high prevalence
and chronicity of migraine translates to a major
burden on health resources and economic burden due
to loss of productivity (2). Despite this, migraine is
often overlooked in health care agendas and there is
surprisingly little data regarding the eﬀectives of POP
for migraine, in particular, there being no randomized
trials. Although this meta-analysis shows promising
treatment eﬀects of the desogestrel POP for migraine,
there is a critical need for further prospective, cohort or
randomised trials examining the eﬀects of hormonal
contraceptives for migraine treatment in general.
Intuitively, the modest beneﬁt identiﬁed in this paper
would translate to signiﬁcantly larger outcomes over a
lifetime when followed for longer timeframes. More
consistency in the use of the International Headache
Society guidelines on migraine research (22), particu-
larly in use of migraine frequency measures and calcu-
lation of headache intensity, will facilitate more reliable
comparison of study results. In light of the variability in
treatment response documented by two studies (28,33),
further studies should also focus on the identiﬁcation of
patient and migraine features that might predict a
favourable response to hormonal contraceptives.
In addition, the eﬀects of other frequently used pro-
gestin-only contraceptives, such as the etonogestrel
implant and the LNG-IUS, on migraine have not
been studied. Further research on other doses of the
desogestrel POP, as well as other progestin formula-
tions, may be warranted. POPs appear to be acceptable
to and safe for a signiﬁcant proportion of women, but
our understanding of their eﬀects on migraine is cur-
rently incomplete.
Implications for clinical practice
This meta-analysis supports the emerging role of the
POP, speciﬁcally the desogestrel POP, for migraine in
women with both MO and MA. The POP was asso-
ciated with signiﬁcant improvements in migraine
symptoms and reduction in acute medication polyphar-
macy over a short follow-up period of 180 days.
Although these improvements are modest in terms of
clinical eﬀect, the beneﬁts and improvements associated
with these small changes in migraine symptoms, espe-
cially in larger populations of women, could result in a
signiﬁcantly-reduced global burden of disease.
Furthermore, it appears that the clinical eﬀects of the
POP on migraine are much greater in some women
than others, and seem to result in signiﬁcant clinical
improvement for up to 60% women (28).
Desogestrel is a highly-selective third generation
progestin with low androgenic activity. The 75mcg/
day formulation is not widely used in the United
States and is unavailable in Australia, but is used fre-
quently in European countries such as Sweden (18,38).
As a relatively high dose of daily progestin (compared
to other progestin-only ‘mini-pills’), it inhibits ovula-
tion in 99% of cycles (39,40) and may lead to amenor-
rhoea (41). These eﬀects are both likely contributors to
its positive eﬀects on migraine symptoms. Progesterone
is also postulated to have direct eﬀects on the nocicep-
tive pathways in the trigeminovascular system (42) and
administration of synthetic progestins can modulate
oestrogen variation by inhibiting ovulation. An advan-
tage of the desogestrel POP is its safety for use in
women with a range of comorbid conditions, including
migraine with aura and hypertension (14,43). However,
like other progestin-only contraceptives, the desogestrel
POP can cause unfavourable bleeding patterns (e.g. fre-
quent or irregular bleeding and prolonged bleeding),
which occur as result of the continuous progestin eﬀects
on the endometrium and can be a reason for treatment
cessation (44,45). Further, the impacts of long-term
anovulation, such as osteoporosis risk, need to be con-
sidered in this cohort. At the time of writing, no pub-
lished data on bone mineral density and fracture risk in
desogestrel users was available.
Pre-menopausal women with migraine frequently
present to neurologists, reproductive health physicians
and primary care physicians with the clinical dilemma
of optimal hormonal contraceptive manipulation. This
dilemma requires a careful multi-disciplinary approach
that considers the individual woman’s migraine diagno-
sis (with or without aura), comorbid risk factors,
gynaecological conditions such as endometriosis or
heavy menstrual bleeding, and preferences around
bleeding patterns. Specialist members of the multi-dis-
ciplinary team need to be aware that medications may
often interact in these women. For example, the COC
may worsen migraine, and certain migraine preventa-
tive treatments (e.g. topiramate) may act as hepatic
enzyme inducers and reduce circulating hormone
levels, potentially compromising contraceptive eﬃcacy.
Women also require signiﬁcant education and
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counselling around their hormonal contraceptive
options and their associated adverse eﬀects, so they
can be informed participants in this decision-making.
This meta-analysis provides data that may help a
woman and her treating physicians decide whether
desogestrel 75mcg/day, if available, will suit her clinical
needs. It appears that for the majority of women, des-
ogestrel 75mcg/day will provide eﬀective contracep-
tion, which may additionally and modestly improve
migraine symptoms.
Clinical implications
. The desogestrel 75mcg/day POP is associated with modest reductions in migraine frequency and duration as
well as reduced use of analgesics and triptans after 180 days’ use in most women.
. Evidence is observational and future prospective, randomised trials will assist in determining the true clinical
eﬀects of the desogestrel POP and other progestin-only contraceptives in migraine treatment.
. The desogestrel POP should be considered in women with migraine, particularly those with common contra-
indications to COC pill use such as migrainous aura and hypertension.
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